Last reviewed · How we verify
NCT04153279
CMV-TCR-T Cells for CM Virus Infection After HSCT
Phase 1 trial testing CMV-TCR-T cells in CMV Infection or Reactivation After Allogenic HSCT in 17 participants. Completed in 15 November 2022.
15 November 2022
Quick facts
| Lead sponsor | Hebei Yanda Ludaopei Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 17 |
| Start date | 19 December 2019 |
| Primary completion | 15 November 2022 |
| Estimated completion | 15 November 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- CMV-TCR-T cells — full drug profile →
Conditions studied
- CMV Infection or Reactivation After Allogenic HSCT — all drugs for CMV Infection or Reactivation After Allogenic HSCT →
Sponsor
Hebei Yanda Ludaopei Hospital
Who can join
Adults 1 to 70, any sex, with CMV Infection or Reactivation After Allogenic HSCT. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single cente, single arm, open-label, phase I study to evaluate the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating CMV virus infection after HSCT.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Human cytomegalovirus: pathogenesis, prevention, and treatment.
Shang Z, Li X. · · 2024 · cited 19× · PMID 39585514 · DOI 10.1186/s43556-024-00226-7 -
Efficacy of pp65-specific TCR-T cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation.
Liu G, Chen H, Cao X, Jia L, et al · · 2022 · cited 14× · PMID 36054234 · DOI 10.1002/ajh.26708 -
ScRNA-seq reveals novel immune-suppressive T cells and investigates CMV-TCR-T cells cytotoxicity against GBM.
Long X, Zhang Z, Li Y, Deng K, et al · · 2024 · cited 10× · PMID 38688579 · DOI 10.1136/jitc-2024-008967 -
Engineering TCR-directed T-cells for the treatment of multiple myeloma.
Mubin N, Ignatz-Hoover JJ, Driscoll JJ. · · 2026 · PMID 41988204 · DOI 10.3389/fimmu.2026.1755096
Verify or expand the search:
- PubMed search for NCT04153279
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CMV-TCR-T cells
Trials testing the same drug.
- NCT05140187 — CMV-TCR-T Cells for CMV Infection After Allogenic HSCT · Phase 1 · unknown
Other Hebei Yanda Ludaopei Hospital trials
Trials by the same sponsor.
- NCT05590091 — Study on Intelligent Nutrition Support Therapy for Hematopoietic Stem Cell Transplantation Recipients · NA · unknown
- NCT05518357 — LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia · Phase 1 · completed
- NCT04508842 — CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL) · Phase 1 · terminated
- NCT04260945 — CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients · Phase 1 · completed
- NCT04260932 — CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04153279 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hebei Yanda Ludaopei Hospital
- Last refreshed: 12 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04153279.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing